Drug intelligence / Profile preview

milgamma

Development stage
Unknown
Lead developer
Wörwag Pharma
Modality
Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration
Oral, Intramuscular
01

Overview

Milgamma is a brand name for a range of pharmaceutical and dietary supplement products containing combinations of B vitamins—primarily benfotiamine (a fat-soluble derivative of vitamin B1), pyridoxine hydrochloride (vitamin B6), and in some formulations cyanocobalamin (vitamin B12). The main mechanism involves replenishing these essential micronutrients to treat or prevent neurological disorders caused by their deficiency. Benfotiamine is absorbed more efficiently than standard thiamine and is converted in the body to active vitamin B1. Pyridoxine supports nerve metabolism as vitamin B6. Cyanocobalamin provides vitamin B12 for nerve health. These combinations are used primarily for neuropathies and other neurological conditions associated with deficiencies in these vitamins[1][2][4][5][7][10]. Injectable forms may also contain lidocaine to reduce injection discomfort[5][10].

Brand names
MilgammaMilgamma 100Milgamma100Milgamma-100Milgamma 300Milgamma300Milgamma-300Milgamma compositumMilgamma monoMilgamma NMilgamma Protectmilgamma protekt
Other names
Vitamin B complex
02

Targets

PDXK (Pyridoxal kinase)THTR (Thiamine transporter 1)Cobalamin transport proteins

Beyond the preview

Go deeper on milgamma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on milgamma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call